Macrophage ATP citrate lyase deficiency stabilizes atherosclerotic plaques

Macrophage ATP citrate lyase deficiency stabilizes atherosclerotic plaques

Inhibition of the metabolic enzyme ATP-citrate lyase can attenuate atherosclerosis by preventing dyslipidemia and potentially also by reducing macrophage-mediated inflammation. Here, the authors show that specific targeting of ACLY in macrophages results in more stable atherosclerotic plaques.

Guardado en:
Detalles Bibliográficos
Autores principales: Jeroen Baardman, Sanne G. S. Verberk, Saskia van der Velden, Marion J. J. Gijbels, Cindy P. P. A. van Roomen, Judith C. Sluimer, Jelle Y. Broos, Guillermo R. Griffith, Koen H. M. Prange, Michel van Weeghel, Soufyan Lakbir, Douwe Molenaar, Elisa Meinster, Annette E. Neele, Gijs Kooij, Helga E. de Vries, Esther Lutgens, Kathryn E. Wellen, Menno P. J. de Winther, Jan Van den Bossche
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/2c0a011d044046398f11e576a0b58fa9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Inhibition of the metabolic enzyme ATP-citrate lyase can attenuate atherosclerosis by preventing dyslipidemia and potentially also by reducing macrophage-mediated inflammation. Here, the authors show that specific targeting of ACLY in macrophages results in more stable atherosclerotic plaques.

Ejemplares similares